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We describe an immunocompetent 19-year-old man with CD20-
positive primary central nervous system (CNS) lymphoma
refractory to chemotherapy and irradiation. After intraventricular
administration of rituximab, a chimeric anti-CD20 monoclonal
antibody, supplemented with autologous serum, a remarkable
response developed to the CNS parenchymal lymphoma.
Cytotoxicity assays showed that untreated patient’s serum with
rituximab, but not that of heat-inactivated patient’s serum with
rituximab or rituximab alone, induced potent rituximab-mediated
cytotoxicity against tumor cells in the patient’s cerebrospinal
fluid, suggesting induction of complement-dependent cytotoxicity
against CNS lymphoma. (Cancer Sci 2006; 97: 80–83)
Despite the high complete remission rate achieved withthe most advanced current therapies, 70–80% of
patients with primary central nervous system (CNS)
lymphoma are treatment refractory or experience relapse.(1–3)
Patients with this condition are less likely to have durable
remission with survival after progression of 2–4 months.(3,4)
Rituximab, a human–mouse chimeric anti-CD20 monoclonal
antibody, induces potent complement-dependent cytotoxicity
(CDC) and antibody-dependent cell-mediated cytotoxicity
(ADCC) in extra-neural non-Hodgkin’s lymphoma of B-cell
origin.(5–10) It might also be efficacious for the treatment of
CNS lymphoma, as more than 90% of primary CNS lympho-
mas are B-cell neoplasms expressing CD20,(11) and CD20 is
not expressed on normal neurons or glia in the brain. How-
ever, the potential efficacy of intravenous rituximab in the
treatment of primary CNS lymphoma is limited by the high
molecular weight of rituximab (146 kDa), which prevents its
entry into the CNS though the blood–brain barrier.(12,13) Phar-
macokinetic studies have estimated that levels of rituximab in
cerebrospinal fluid (CSF) are 1% or less of those in serum for
patients with primacy CNS lymphoma or systemic non-Hodg-
kin’s lymphoma.(12,13) Furthermore, rituximab given intrathe-
cally or intraventricularly has not been shown to have
substantial therapeutic effects on CNS parenchymal lym-
phoma,(13) suggesting that such an approach alone is unable to
produce beneficial cytotoxic activity against CNS lymphoma
refractory to conventional therapy. To overcome this
dilemma, a patient with refractory primary CNS lymphoma
was intraventricularly administered autologous serum in
addition to rituximab, which produced a remarkable tumor
response, probably by induction of CDC.
Case Report
A 19-year-old man presented in March 2003 with a 2-week
history of diplopia and headache that continued until
resection of a brain tumor. Computed tomographic (CT)
scanning of the brain followed by brain and spinal magnetic
resonance imaging showed an enhancing mass in the left
parietal lobe with surrounding vasogenic edema and right
midline shift. Histology from a subtotal tumor resection
revealed a CD20-positive diffuse large B-cell lymphoma that
was negative for CD3, CD5, CD10 and Epstein–Barr virus-
encoded small RNA. There was no evidence of congenital
immunodeficiency in this patient, nor was there history of
exposure to immunosuppressive drugs. The patient was also
seronegative for human immunodeficiency virus. CT scans of
the chest and abdomen, pelvis bone marrow biopsy sample,
and positron emission tomography imaging revealed no
lymphoma outside the CNS, confirming the diagnosis of
primary CNS lymphoma. There had been no evidence of
leptomeningeal lymphoma involvement throughout the
overall course. Brain CT at the initiation of chemotherapy in
April 2003 showed a residual tumor in the left lateral
ventricle. Four cycles of high-dose methotrexate, 8 g/m2
every 14 days,(14) failed to produce a response, prompting
salvage therapy. The patient received whole brain irradiation
with a dose of 3600 cGy followed by involved field
irradiation with 900 cGy, and systemic and intrathecal
chemotherapy (methotrexate, cytarabine [Ara-C] and
prednisolone). Despite intensive treatment, CNS lymphoma
progressed with development of hydrocephalus that required
external ventricular drainage using an Ommaya reservoir
(Fig. 1A–C).
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In view of the low probability of response to other forms
of systemic therapy, intraventricular administration of rituxi-
mab along with autologous serum was planned, based on our
in vitro studies showing that coadministration of patient’s
serum is required for effective treatment of CNS lymphoma
with intracranial rituximab.(15) The patient gave written
informed consent to participate in this investigational proto-
col, which was approved by the institutional review board. In
November 2003, the patient received intraventricular admin-
istrations of rituximab; 10 mg (1 mL), 40 mg (4 mL) and
50 mg (5 mL) on days 1, 3 and 6, respectively, concomitant
with 8 mL of autologous serum taken several days before ini-
tiation of rituximab therapy. No diluting agents except for
autologous serum were added. Intraventricular rituximab
injections (10 mg/9 mL, 40 mg/12 mL and 50 mg/13 mL,
respectively) were carried out over 5 min via Ommaya
reservoir. Prior to administration of intraventricular rituximab
and autologous serum, an equivalent volume of CSF was
removed. While there were no adverse events, including
neurotoxicity, the patient’s clinical condition continued to
deteriorate over the next 4 weeks, leading to obtunded
consciousness and bradycardia. Disease progression was
confirmed radiologically by CT (Fig. 1D–F). At that time, the
patient and his family declined additional therapy, and he was
provided the best supportive care.
Unexpectedly, the patient recovered consciousness
8 weeks after intraventricular rituximab treatment. CT
showed a partial radiographic response with resolution of
hydrocephalus and improvement of brain edema (Fig. 1G–I),
which remained until 12 weeks after intraventricular rituxi-
mab treatment. Unfortunately, because the patient developed
serious aspirating pneumonia immediately after we became
aware of the disease response, he was not given additional
intraventricular treatment with rituximab and autologous
serum. His consciousness worsened again around 10 weeks
after intraventricular rituximab treatment, and brain CT
14 weeks after rituximab treatment confirmed regrowth of the
CNS lymphoma. The patient died of lymphoma 121 days
after the course of intraventricular rituximab treatment.
Materials and Methods
Cell lines
Epstein–Barr virus-immortalized lymphoblastoid B-cell line
(LCL) and CD20-positive lymphoma cell line IM9 were used
in the present study. Cell lines were maintained in RPMI
Fig. 1. Response of primary central nervous
system lymphoma to chemotherapy,
radiation therapy and autologous serum-
supplemented intraventricular rituximab
therapy. (A–C) Computed tomography (CT)
after 7 months of chemotherapy and
radiation therapy shows multiple enhancing
masses in the left lateral ventricle (arrow),
third ventricle (arrowheads) and left caudate
nucleus (*) with hydrocephalus and adjacent
edema. (D–F) CT obtained 4 weeks after
treatment with intraventricular rituximab
together with autologous serum shows the
brain masses increasing in size. (G–I) CT
obtained 8 weeks after treatment show a
substantial decrease in the size of the tumor,
resolution of the hydrocephalus and
improvement of brain edema.
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1640 (Gibco Laboratories, Grand Island, NY, USA), 10%
heat-inactivated fetal calf serum (Gibco Laboratories),
2 mmol/L l-glutamine (Gibco Laboratories) and penicillin–
streptomycin (Gibco Laboratories). Cells in the late
logarithmic phase of growth were used for cell-killing assays.
Antibodies and flow cytometry
The chimeric anti-CD20 monoclonal antibody rituximab was
purchased from Roche Pharmaceuticals (Basel, Switzerland).
Mouse fluorochrome-conjugated isotype control antibodies
were purchased from Becton Dickinson (Franklin Lakes, NJ,
USA). Three-color flow cytometric phenotyping of target
cells was carried out on a FACScan flow cytometer (Becton
Dickinson, Mountain View, CA, USA). Saturating amounts
of antibodies were added to cells for 30 min at 4°C, before
extensive washing and analysis.
Rituximab-mediated cell lysis in the presence of CSF
Target cells (1 × 106/mL) were incubated in CSF obtained
from the present patient prior to intraventricular rituximab
administration. The CSF was passed through 0.22-µm filters
(Millipore, Bedford, MA, USA) before use. Cultures
containing either 10 µg/mL rituximab or no rituximab were
supplemented with autologous patient serum that was heat
inactivated at 56°C for 30 min or non-heat inactivated
(untreated). After various times at 37°C, lysis of cells was
determined flow cytometrically by uptake of propidium
iodide (Becton Dickinson).
Pharmacokinetics
Rituximab concentrations were determined by enzyme-linked
immunosorbent assay.(16) Analysis of rituximab concentrations
was carried out in FALCO biosystems (Kyoto, Japan) but not
in our institute.
Results and Discussion
To test the in vitro cytotoxicity of rituximab in the presence
of patient CSF, we carried out kinetic and dose–response
experiments using LCL cells and the CD20-positive
lymphoma cell line IB9 as targets. In the presence of patient
CSF, the addition of untreated patient’s serum along with
rituximab induced time-dependent killing of both target cells,
whereas the addition of heat-inactivated autologous serum
along with rituximab or rituximab alone induced no
considerable killing of target cells (Fig. 2A,B). Both target
cells were lysed with only 10% serum-supplemented
rituximab, and cytotoxicity against target cells appeared to be
independent of increasing concentrations of serum (Fig. 2C).
Levels of complement proteins C3 and C4 in the patient’s
serum were within reference intervals, in contrast to those in
the patient’s CSF that were lower than detectable levels.
These findings suggest that concomitant administration of
serum with rituximab into the craniospinal axis, but not the
use of rituximab alone, activates rituximab-mediated CDC,
leading to killing of tumor cells.
The CSF concentration of rituximab just before the third
intraventricular injection in our patient was 12.8 µg/mL, an
amount sufficient to induce lysis of lymphoma cells accord-
ing to our in vitro studies (Fig. 2). These findings support the
possibility of in vivo development of CDC in the patient’s
CNS, because concentrations of rituximab within the cere-
brospinal axis were likely to have surpassed 10 µg/mL at
least for 72 h.
Besides CDC, a potent mechanism of rituximab-dependent
lymphoma cell killing is ADCC. Monocytes, natural killer
cells and polymorphonuclear leukocytes have all been shown
to kill opsonized lymphoma cells.(5,6) Therefore, primary
CNS lymphoma cells could be cleared by intraventricular or
intrathecal administration of such cellular effectors in addi-
tion to rituximab. This approach may be another treatment
option for primary CNS lymphoma, in addition to the combi-
nation of serum-supplemented rituximab and other chemo-
therapeutic drugs within the cerebrospinal axis.
Fig. 2. Rituximab-mediated cell lysis in the presence of the patient’s
cerebrospinal fluid depends on the presence of autologous non-
heat-inactivated serum. (A) CD20-positive lymphoblastoid B-cell line
(LCL) cells or (B) CD20-positive lymphoma cell line IB9 cells were
incubated for the indicated time in patient cerebrospinal fluid (CSF)
supplemented with either heat-inactivated or non-heat-inactivated
patient serum in the presence or absence of 10 µg/mL rituximab. (C)
CD20-positive LCL cells () or CD20-positive lymphoma cell line IB9
cells () were incubated for 3 h in patient CSF in the presence of
10 µg/mL rituximab with increasing concentrations of patient serum.
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To our knowledge, this is the first report of a positive
response in the treatment of primary CNS lymphoma following
administration of autologous-serum-supplemented rituximab
within the cerebrospinal axis. The response is particularly
remarkable given the disease progression during prior
treatment with cytotoxic chemotherapy and irradiation, and
the comatose state of the patient at the start of rituximab
therapy.
Our observations form a striking contrast to a previous
study,(13) which reported that intraventricular administration
of rituximab alone was ineffective against a parenchymal
lesion, despite its substantial efficacy in leptomeningeal dis-
ease. One possible explanation is that effector mechanisms
such as CDC and ADCC may be mandatory to eliminate
parenchymal lymphoma cells by rituximab, while leptome-
ningeal lymphoma cells may be eradicated by direct induc-
tion of apoptosis(5) via contact with rituximab in the CSF
without the effector mechanisms.
It is notable that it took 8 weeks after the intraventricular
administration of rituximab until our patient developed clini-
cal improvement and tumor reduction following the transient
exacerbation. The clinical data cannot easily be agreeable
with immediate killing in short-term in vitro assays (Fig. 2).
However, this may be explained by a previous report showing
the occasional lag between rituximab infusion and therapeu-
tic effect.(17) Of 49 patients who received rituximab as a sin-
gle first-line therapy, 10 patients had clinical responses
between 2 and 11 months after rituximab, whereas 36
patients responded within 2 months after rituximab treat-
ment. These findings suggest the involvement of late effec-
tors such as dendritic cells and T lymphocytes in the effector
mechanisms of rituximab. Selenko et al.(18) demonstrated that
rituximab treatment of CD20+ lymphoma cells induces
uptake and cross-presentation of lymphoma cell-derived pep-
tides on dendritic cells, which finally allows an efficient acti-
vation of specific T lymphocytes. Although it is unknown
whether these reactions could occur in the CNS, the hypoth-
esis may be supported by several observations that glial cells
such as microglia can gain antigen-presenting capacity
through the expression of major histocompatibility complex
molecules in patients with brain tumors,(19) that rituximab
promotes release of proinflammatory cytokines such as tumor
necrosis factor (TNF)-α,(20) and that resident brain cells can
synthesize TNF-α capable of allowing invasion of T lym-
phocytes into the affected brain tissue.(19)
There were no adverse events resulting from treatment
with intraventricular autologous-serum-supplemented rituxi-
mab, which offers new hope for a disease that until now has
been associated with a poor prognosis.(2,4,11,13) Further refine-
ments of this therapy might lead to effective treatment of pri-
mary CNS lymphoma refractory to conventional therapy.
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